Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway

Mar 12, 2022Phytomedicine : international journal of phytotherapy and phytopharmacology

Tubeimoside-I helps overcome chemotherapy resistance in brain cancer cells by lowering a repair protein and blocking a growth signaling pathway

AI simplified

Abstract

Tubeimoside-I (TBMS1) significantly sensitized TMZ-resistant glioblastoma cells to chemotherapy.

  • TBMS1 promoted apoptosis and inhibited cell viability, proliferation, and clone formation in resistant glioblastoma cells.
  • A notable synergistic effect between TBMS1 and temozolomide (TMZ) was indicated by the coefficient of drug in interaction (CDI) values.
  • The combination of TBMS1 and TMZ led to increased DNA damage, as evidenced by robust double-strand breaks and γH2AX foci formation.
  • Key apoptotic markers, including increased cleaved PARP and a heightened Bax/Bcl-2 ratio, were observed following treatment.
  • Reduction of MGMT expression was associated with the enhanced effects of TBMS1 and TMZ in resistant glioblastoma cells.
  • Inhibition of the EGFR-induced PI3K/Akt/mTOR/NF-κB signaling pathway was linked to the synergistic anti-glioma effects.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free